Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib vs Sunitinib in Advanced Metastatic Renal Cell Cancer
NCT01829841Phase 2Completed
- Sponsor
- Hengrui
- Start
- May 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of famitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Hengrui. Primary endpoint: Objective Response Rate at 18 weeks. Started May 2011; status: completed.
02
Drugs
famitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01829841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01829841.